MedTrace Logo

Study Evaluating the Olfactory Recovery of Anosmia Post COVID-19 by Olfactory Rehabilitation Assisted by Web-application

NCT04806880 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1155

Last updated 2021-10-11

No results posted yet for this study

Summary

Anosmia is a symptom present in 40 to 80% of patients and usually only lasts 1 to 2 weeks. However, in nearly one in five patients, it can last beyond or even several months with consequences in terms of undernutrition and depression. However, olfactory rehabilitation is a technique validated in post-infectious anosmia since 2014 and recommended by international learned societies to accelerate recovery with nearly 63% improvement in anosmia In the context of the health crisis linked to the coronavirus, approximately 1 million French people will have persistent anosmia following an infection with COVID-19. A web-application to support the olfactory coaching of anosmic patients and help with follow-up seems relevant to promote recovery and the proper conduct of this coaching.

covidanosmie.fr is a web application dedicated to olfactory rehabilitation, accessible free of charge.

Conditions

  • Covid19

Interventions

DEVICE

Web-application

support for olfactory coaching consisting of the inhalation of fragrant essential oils.

Sponsors & Collaborators

  • Kelindi

    collaborator INDUSTRY

  • Centre National de la Recherche Scientifique, France

    collaborator OTHER

  • Hospital of Tours

    collaborator UNKNOWN

  • Weprom

    lead OTHER

Principal Investigators

  • Fabrice DENIS, MD · Weprom

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-25
Primary Completion
2021-08-01
Completion
2021-08-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04806880 on ClinicalTrials.gov